Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, et al. (2018)  PLoS ONE 13(12): e020…

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Therap Adv Gastroenterol. 2018 Dec 2;…

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Villani R, Vendemiale G, Serviddio G. Int J Mol Sci. 2018 Dec 22;20(1). pii: E49. doi: 10.3390/ijms20010049. Review. https://www.mdpi.com/1422-0067/20/1/49

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. (2018)  PLoS ONE 13(12): e0209374. doi.org/10.1371/journal.pone.02093…

Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. Welz M, Eickhoff S, Abdullah Z, Trebicka J, Gartlan KH, Spicer JA, Demetris AJ, Akhlaghi H, Anton M, Manske K, Zehn D, Nieswandt B, Kurts C, Trapani JA, K…

Barriers and facilitators to hepatitis C (HCV) screening and treatment—a description of prisoners’ perspective Des Crowley, Marie Claire Van Hout, John S. Lambert, Enda Kelly, Carol Murphy and Wal…